The open label, randomized, multicenter, phase 2b/3 DIVERSITY trial evaluated the efficacy and safety of dabigatran compared with SOC (low molecular weight heparin or vitamin K antagonist) in 240 children.
Your search for dabigatran returned 110 results
Efficacy similar to aspirin for preventing recurrent stroke after embolic stroke of undetermined source
The primary efficacy outcome was the combined rate of death from a cardiovascular cause, heart attack, stroke due to inadequate blood supply, blood clots or amputation due to cardiovascular disease.
Researchers performed a retrospective cohort study to compare incidence of stroke, bleeding, and myocardial infarction in patients with atrial fibrillation initiating dabigatran or warfarin (n=25,289 for each) from November 2010 to May 2014.
The primary safety endpoint was defined as time to major bleeding events and clinically relevant non-major bleeding events when compared to triple therapy with warfarin.
Effective for dabigatran reversal among patients with uncontrolled bleeding, undergoing urgent surgery
Pollack, CV et al. “Idarucizumab for Dabigatran Reversal — Full Cohort Analysis.” DOI: 10.1056/NEJMoa1707278
The data represents ~3,000 patients who had received the study drug in Phase 3 of GLORIA-AF with up to 2 years follow-up.
Combining dabigatran with certain statin medications could raise the odds for major hemorrhage in patients with atrial fibrillation, according to a study published online in CMAJ, the journal of the Canadian Medical Association.
Increase in risk of intracranial hemorrhage, major GI bleeding in a-fib patients taking rivaroxaban